Hsbc Holdings PLC Sells 103,748 Shares of Waters Corporation $WAT

by · The Markets Daily

Hsbc Holdings PLC lowered its holdings in Waters Corporation (NYSE:WAT – Free Report) by 20.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 395,352 shares of the medical instruments supplier’s stock after selling 103,748 shares during the period. Hsbc Holdings PLC’s holdings in Waters were worth $150,096,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of WAT. Pinnacle Associates Ltd. raised its stake in shares of Waters by 0.3% during the 4th quarter. Pinnacle Associates Ltd. now owns 7,608 shares of the medical instruments supplier’s stock worth $2,890,000 after purchasing an additional 26 shares during the period. Exencial Wealth Advisors LLC grew its position in Waters by 1.7% during the fourth quarter. Exencial Wealth Advisors LLC now owns 1,681 shares of the medical instruments supplier’s stock valued at $638,000 after buying an additional 28 shares during the period. Rosenberg Matthew Hamilton grew its position in Waters by 8.8% during the fourth quarter. Rosenberg Matthew Hamilton now owns 359 shares of the medical instruments supplier’s stock valued at $136,000 after buying an additional 29 shares during the period. Clearstead Advisors LLC grew its position in Waters by 5.1% during the fourth quarter. Clearstead Advisors LLC now owns 616 shares of the medical instruments supplier’s stock valued at $234,000 after buying an additional 30 shares during the period. Finally, Integrated Wealth Concepts LLC increased its holdings in Waters by 2.9% during the first quarter. Integrated Wealth Concepts LLC now owns 1,048 shares of the medical instruments supplier’s stock worth $386,000 after buying an additional 30 shares during the last quarter. Institutional investors own 94.01% of the company’s stock.

Analysts Set New Price Targets

WAT has been the topic of several research reports. Bank of America lifted their price objective on shares of Waters from $370.00 to $400.00 and gave the stock a “neutral” rating in a research report on Tuesday, June 2nd. TD Cowen raised their price target on shares of Waters from $345.00 to $385.00 and gave the stock a “hold” rating in a research note on Wednesday, May 6th. JPMorgan Chase & Co. raised their price target on shares of Waters from $330.00 to $345.00 and gave the stock a “neutral” rating in a research note on Wednesday, May 6th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a $350.00 price target on shares of Waters in a report on Thursday, May 7th. Finally, Evercore upgraded Waters from an “in-line” rating to an “outperform” rating and set a $350.00 price objective on the stock in a research note on Monday, April 6th. Three research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $394.56.

Check Out Our Latest Analysis on WAT

Waters Price Performance

WAT opened at $356.26 on Friday. The firm has a 50-day moving average price of $342.66 and a 200-day moving average price of $348.56. Waters Corporation has a twelve month low of $275.05 and a twelve month high of $414.15. The company has a quick ratio of 1.13, a current ratio of 1.79 and a debt-to-equity ratio of 0.32. The company has a market capitalization of $34.98 billion, a price-to-earnings ratio of 45.27, a PEG ratio of 2.15 and a beta of 1.21.

Waters (NYSE:WAT – Get Free Report) last announced its quarterly earnings results on Tuesday, May 5th. The medical instruments supplier reported $2.70 EPS for the quarter, beating analysts’ consensus estimates of $2.31 by $0.39. The company had revenue of $1.27 billion for the quarter, compared to analysts’ expectations of $1.20 billion. Waters had a net margin of 11.91% and a return on equity of 15.60%. Waters’s revenue was up 91.4% compared to the same quarter last year. During the same period in the prior year, the company posted $2.25 EPS. Waters has set its Q2 2026 guidance at 2.950-3.050 EPS and its FY 2026 guidance at 14.400-14.600 EPS. Equities analysts expect that Waters Corporation will post 14.51 EPS for the current year.

Waters Company Profile

(Free Report)

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.

Read More

Want to see what other hedge funds are holding WAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Waters Corporation (NYSE:WAT – Free Report).